Very high dose chemotherapy with autologous bone marrow rescue in adult patients with resistant relapsed lymphoma

Cancer Chemother Pharmacol. 1986;16(2):170-5. doi: 10.1007/BF00256170.

Abstract

Seventeen patients with advanced lymphoma were treated with high-dose chemotherapy with autologous bone marrow rescue. In 11 patients with non-Hodgkin's lymphoma (NHL) there were 2 complete remissions (CRs) and 2 partial remissions (PRs), and in 6 patients with Hodgkin's disease there were 5 CRs. Three patients remain well in unmaintained remission (days 874, 446 and 351), and a further 2 are alive and still receiving treatment (days 650 and 558). This type of therapy appears useful and should now be considered earlier in the course of the disease.

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Bone Marrow Transplantation*
  • Carmustine / therapeutic use
  • Cyclophosphamide / therapeutic use
  • Cytarabine / therapeutic use
  • Female
  • Hodgkin Disease / drug therapy*
  • Hodgkin Disease / therapy
  • Humans
  • Lymphoma / drug therapy*
  • Lymphoma / therapy
  • Male
  • Melphalan / therapeutic use
  • Methotrexate / therapeutic use
  • Middle Aged
  • Podophyllotoxin / therapeutic use

Substances

  • Cytarabine
  • Cyclophosphamide
  • Podophyllotoxin
  • Melphalan
  • Carmustine
  • Methotrexate

Supplementary concepts

  • BEAM protocol
  • UCH I protocol
  • UCH II protocol